DK2059234T3 - Fremgangsmåde til at lindre inflammation i fordøjelseskanalen - Google Patents

Fremgangsmåde til at lindre inflammation i fordøjelseskanalen

Info

Publication number
DK2059234T3
DK2059234T3 DK07814746.9T DK07814746T DK2059234T3 DK 2059234 T3 DK2059234 T3 DK 2059234T3 DK 07814746 T DK07814746 T DK 07814746T DK 2059234 T3 DK2059234 T3 DK 2059234T3
Authority
DK
Denmark
Prior art keywords
digestive tract
relieving inflammation
subject
inflammation
reducing
Prior art date
Application number
DK07814746.9T
Other languages
Danish (da)
English (en)
Inventor
Louis Anthony Tartaglia
Thomas Michael Barnes
Robert Mark Coopersmith
Scott Edward Malstrom
David William White
Dominic Picarella
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2059234T3 publication Critical patent/DK2059234T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK07814746.9T 2006-09-08 2007-09-07 Fremgangsmåde til at lindre inflammation i fordøjelseskanalen DK2059234T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82507506P 2006-09-08 2006-09-08
US82780706P 2006-10-02 2006-10-02
PCT/US2007/077857 WO2008031014A1 (en) 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract

Publications (1)

Publication Number Publication Date
DK2059234T3 true DK2059234T3 (da) 2011-11-28

Family

ID=38670723

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07814746.9T DK2059234T3 (da) 2006-09-08 2007-09-07 Fremgangsmåde til at lindre inflammation i fordøjelseskanalen

Country Status (11)

Country Link
US (1) US20080234345A1 (enExample)
EP (1) EP2059234B1 (enExample)
JP (1) JP2010502736A (enExample)
CN (1) CN101568331A (enExample)
AT (1) ATE531362T1 (enExample)
AU (1) AU2007292247A1 (enExample)
CA (1) CA2662535A1 (enExample)
DK (1) DK2059234T3 (enExample)
ES (1) ES2376493T3 (enExample)
IL (1) IL197362A0 (enExample)
WO (1) WO2008031014A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
EP2262491A1 (en) * 2008-03-10 2010-12-22 Ore Pharmaceuticals Inc. Therapy for disorders of the proximal digestive tract
WO2010093804A1 (en) * 2009-02-12 2010-08-19 Ore Pharmaceuticals, Inc. Ace2 inhibitors for reducing gastrointestinal adverse effects of cytotoxic agents
EP2543388A4 (en) * 2010-03-04 2013-11-27 Dainippon Sumitomo Pharma Co MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
GB202116266D0 (en) * 2021-11-11 2021-12-29 Bicycletx Ltd Novel use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
US6632830B1 (en) * 1999-04-30 2003-10-14 Millennium Pharmaceuticals, Inc. ACE-2 inhibiting compounds and methods of use thereof
WO2002098448A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
GB0203061D0 (en) 2002-02-08 2002-03-27 Novartis Ag Organic compounds
JP2006503905A (ja) * 2002-09-24 2006-02-02 コンビナトアールエックス インコーポレーティッド 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬
TW200902047A (en) * 2003-02-14 2009-01-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050203168A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of Michigan Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
US7842709B2 (en) * 2006-09-08 2010-11-30 Ore Pharmaceuticals Inc. Method for treating inflammatory diseases of the digestive tract

Also Published As

Publication number Publication date
ES2376493T3 (es) 2012-03-14
AU2007292247A2 (en) 2009-03-26
EP2059234B1 (en) 2011-11-02
WO2008031014A1 (en) 2008-03-13
AU2007292247A1 (en) 2008-03-13
ATE531362T1 (de) 2011-11-15
IL197362A0 (en) 2009-12-24
US20080234345A1 (en) 2008-09-25
CA2662535A1 (en) 2008-03-13
EP2059234A1 (en) 2009-05-20
JP2010502736A (ja) 2010-01-28
CN101568331A (zh) 2009-10-28

Similar Documents

Publication Publication Date Title
DK2059234T3 (da) Fremgangsmåde til at lindre inflammation i fordøjelseskanalen
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
WO2009055783A3 (en) Anti-pcsk9 and methods for treating lipid and cholesterol disorders
WO2008016887A3 (en) Methods and pharmaceutical compositions to treat gastric acid disorders
EA201500769A1 (ru) Ингибиторы е1 активирующих ферментов
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
WO2010068794A3 (en) Hif inhibitors and use thereof
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201001496A1 (ru) Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
MX337634B (es) Anillos intravaginales monoliticos que comprenden progesterona y metodos de manufactura y uso de los mismos.
EA201101435A1 (ru) Имидазотиадиазолы для применения в качестве ингибиторов киназ
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
WO2010062900A3 (en) A new family of pain producing substances and methods to produce novel analgesic drugs
TR201907241T4 (tr) IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2.
GEP20125458B (en) Matrix metalloproteinase inhibitors
WO2008106166A3 (en) Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors
WO2006132959A3 (en) Inhibition of thrombin generation
EP2225196A4 (en) CYSTONE PROTEASE INHIBITOR FOR THE TREATMENT OF PARASITIC DISEASES
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios
WO2007084651A3 (en) Methods and kits to treat chronic inflammatory immune diseases
MX2011004870A (es) Composicion de combinacion que comprende un inhibidor de dhodh y metotrexato para tratar enfermedades autoinmunes.
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
WO2009155070A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
WO2007097980A3 (en) Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy